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ABSTRACT 
 
Atopic dermatitis is a chronic, debilitating disease affecting children worldwide, with 
increasing prevalence. It has been shown to be a significant problem leading to a 
diminished quality of life, for both the affected patient and their families.  
 
Quality of life in Atopic Dermatitis is poorly researched. Few studies have been 
conducted worldwide. There have been no published reports on QOL in children with 
atopic dermatitis from South Africa. This study aims to assess and evaluate the clinical 
severity of atopic dermatitis in children less than 6 years of age and the Quality of Life 
in these patients and their families, as well as to determine the socioeconomic and 
clinical factors that predict quality of life in children with atopic dermatitis at Chris Hani 
Baragwanath Academic Hospital (the busiest paediatric dermatology clinic in South 
Africa). 
 
The Childhood Atopic Dermatitis Impact Scale (CADIS) and Patient Oriented Eczema 
Measure (POEM) were given to the primary caregiver and the SCORAD was 
performed on each child during a single visit to the Paediatric Dermatology Outpatient 
Clinic at Chris Hani Baragwanath Academic Hospital (CHBAH) in Soweto. 
 
The study parameters show that atopic dermatitis has a negative impact on the quality 
of life of affected children and their families, in keeping with similar studies 
internationally. The severity of atopic dermatitis was a significant predictor of quality 
of life. The poor socioeconomic status was evident in the demographic details of the 
sample. A significant predictor of quality of life was the age of the affected child, with 
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a higher impairment in child and family QOL experienced for children less than 1 year 
of age. The QOL measure showed a higher correlation to the caregiver assessment 
of severity than to the physician’s assessment, suggesting that patient derived 
outcome measures should be of most importance in adequately assessing disease 
severity.   
 
There is a need for further research of children in South Africa with atopic dermatitis. 
This is essential to identify effective interventions to improve disease severity and 
Q.O.L in these children. This would result in the development of children into healthy 
adults capable of effective family, community and social interaction. 
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Chapter 1: INTRODUCTION 
 
The skin is the largest organ in the body, weighing on average four kilograms. It is 
a complex structure that forms a protective barrier between the body and the 
external environment. It is a sensory organ and is involved in the maintenance of 
water and electrolyte balance, as well as temperature regulation (Hunter et al., 
2002). 
 
The skin is a measure and window of one’s physical appearance and beauty. 
Severe dermatological disorders lead to significant impairment in quality of life 
(QOL) with social embarrassment and a decrease in self-esteem in affected 
patients. 
 
Impact and burden of the disease 
Atopic Dermatitis (AD) is a common cutaneous disorder globally and it affects 
individuals of all age groups, usually manifesting before 5 years of age (Bolognia et 
al., 2008). 
 
AD is chronic and debilitating. It not only impacts the affected patient but their 
immediate families as well. In the past, management and treatment protocols were 
based exclusively on clinical severity indices which stratified patients into mild, 
moderate and severe atopic dermatitis (eczema). However, with recent evidence 
demonstrating the impact on family life and psychosocial functioning (Case et al., 
2015, Cheng et al., 2015), it is no longer possible to rely solely on these outcome 
measures to monitor effectiveness of treatment. Quality of Life (Q.O.L) measures 
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have been studied to evaluate outcomes for children with chronic health conditions. 
It is also a good index to monitor patient progress and response to provided 
treatment. 
 
The World Health Organisation (WHO) defines Quality of Life as “the individual’s 
perception of their position in life in the context of culture and value systems in which 
they live and in relation to their goals, expectations, standards and concerns” (The 
Whoqol, 1998). Health related Q.O.L measures quality of life only in the context of 
the patient’s medical condition. Overall Q.O.L encompasses impact on family life, 
living circumstances and school functioning (Wallander et al., 2001). 
 
Quality of Life studies in atopic dermatitis have largely been conducted in the 
developed world (Aziah et al., 2002, Ben-Gashir et al., 2002, Balkrishnan et al., 
2003, Ben-Gashir, 2003, Ben-Gashir et al., 2004, Beattie and Lewis-Jones, 2006a, 
Chamlin et al., 2004, McKenna and Doward, 2008), with limited data available in 
the African setting. To our knowledge, no Quality of Life study has ever been 
conducted in children in South Africa with AD. Evidence from European and Asian 
studies suggest that AD has a negative impact on the Q.O.L of affected children 
(Aziah et al., 2002, Ben-Gashir et al., 2004, Chamlin et al., 2004). Some factors that 
may affect these children include negative effect on family life, change in family 
dynamics, poor school performance, stigma associated with the disease and 
negative self-image (Daud et al., 1993, Su et al., 1997). 
 
A variety of Quality of Life indices is available to assess skin disease in children 
(Lewis-Jones and Finlay, 1995, Lewis-Jones et al., 2001, McKenna and Doward, 
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2008). However, most of these tools are not specific to children with atopic 
dermatitis (Chamlin et al., 2005). 
 
The Childhood Atopic Dermatitis Impact Scale (CADIS) is a validated QOL tool 
formulated specifically for children less than 6 years of age with atopic dermatitis 
and their families. It was developed and refined by Chamlin et al, who reviewed 
previous work published on the topic, and conducted interviews with all role-players 
including families, nurses and medical professionals. It comprises 45 questions in 5 
domains, focusing on child and family welfare (Chamlin et al., 2007). 
 
PROBLEM STATEMENT 
Atopic Dermatitis in children has become an increasing psychosocial and financial 
burden (Carroll et al., 2005). It is important to assess the effect on Quality of Life in 
these patients and their families in a South African setting, due to its psychosocial 
and financial burden. 
 
AIM OF THE STUDY 
To assess and evaluate the clinical severity of atopic dermatitis in children less than 
6 years of age and the Quality of Life in these patients and their families. 
 
STUDY OBJECTIVES 
i. To objectively assess the clinical severity of atopic dermatitis in the sample. 
ii. To gain a subjective assessment of severity of the affected child’s atopic 
dermatitis from the primary caregiver. 
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iii. To assess the quality of life as a result of the atopic dermatitis in: 
a) the affected patients and   
b) parents` and families of the affected patient 
iv. To determine whether socioeconomic and demographic parameters predict 
quality of life. 
v. To determine whether clinical severity and perceived disease severity 
correlates with the degree of impairment in quality of life; and which areas of 
quality of life are most impacted. 
 
SIGNIFICANCE OF THE STUDY 
 Measuring quality of life provides important, additional information to the 
standard clinical scoring systems for atopic dermatitis. By assessing the 
Q.O.L of patients and their families, we are able to treat them holistically by 
adopting a patient and family-centred approach to management of atopic 
dermatitis. 
 
 The information gathered on quality of life in children and their families will 
benefit all health care professionals and families involved in the management 
of children suffering from atopic dermatitis. It would assist in identifying 
specific areas where intervention can be directed and resources allocated to 
improve Q.O.L of patients and their families. In addition, specific domains 
assessed using the Childhood Atopic Dermatitis Impact Scale may highlight 
specific aspects of quality of life that are consistently affected by atopic 
dermatitis that may need special consideration. 
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 There is currently a paucity of data regarding quality of life in children with 
atopic dermatitis in South Africa. It is also not known whether socioeconomic 
factors and demographics impact on the perception of quality of life in this 
setting. The results of this study will help to identify specific areas where 
intervention can be directed to improve the quality of life of patients and their 
families afflicted by this disorder in South Africa. 
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Chapter 2: LITERATURE REVIEW 
 
Studies from Western countries suggest that the prevalence of allergic disease may 
be reaching a plateau, but it shows that developing nations (especially in Africa) 
have shown a dramatic increase in these diseases over the last few years (Williams 
et al., 2008). Nicolaou et al illustrated the increase in allergic diseases associated 
with increasing urbanization (2005). The United Nations have estimated that by 
2030 71.3% of South Africans will live in urban areas. This may well explain the 
reason why the prevalence of atopic dermatitis in South Africa is rapidly increasing. 
 
Atopic Dermatitis is a chronic medical condition affecting adults and children. The 
chronic nature of the disease and its increasing prevalence highlights its relevance 
in clinical medicine and the resources that need to be allocated to it. It has therefore 
become increasingly important to study the quality of life in children living with this 
condition. Using Q.O.L as a research tool, we are able to assess the effectiveness 
of treatment and services on the paediatric population. 
 
This literature review discusses the concepts of Quality of Life and the factors 
impacting on Q.O.L in patients with eczema and their families. Key concepts 
discussed include epidemiology, pathogenesis, clinical features of atopic dermatitis 
as well as severity assessment and scoring systems. Standard texts, Pubmed and 
Medline searches were referenced. 
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2.1 Introduction 
Atopic dermatitis (or atopic eczema) is a chronic, pruritic skin disorder affecting both 
adults and children. A chronic childhood disease, as defined by Mokkink et al 
(2008), is one that fulfils four criteria i.e.  
(1) The age of the child must be younger than 18 years 
(2) The diagnosis of the disease is made by the use of scientific knowledge and 
can be reproduced using valid tools and methods 
(3) At the time of diagnosis, the disease has no known cure 
(4) The duration of the condition is more than 3 months 
The above definition looks at the medical aspects of a condition only and does take 
into consideration the broader impact the disease may have on the child. Perrin et 
al (1993) researched the level of functional impairment caused and the amount of 
medical care needed for a chronic childhood disease. By considering these two 
concepts, it is clear why atopic dermatitis is classified as a chronic childhood illness. 
 
The following paragraphs will focus on epidemiology, pathogenesis and clinical 
features of AD to understand the nature of the disease as well as severity scoring 
systems and quality of life issues to elucidate the clinical significance of atopic 
dermatitis. 
 
2.2 Epidemiology 
Most studies in atopic dermatitis have been performed in children. Evidence 
suggests it affects up to 3% of adults and approximately 20% of children, with 
prevalence varying greatly throughout the world (Nutten, 2015). 
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The most extensive AD prevalence and trend data have emerged from the 
International study of Asthma and Allergies in childhood (ISAAC), which analysed 
data from nearly 2 million children in 100 countries. It showed that for children 6-7 
years of age, the prevalence ranged from 0.9% in India to 22.5% in Ecuador. For 
the 13-14 year age group, the prevalence ranged from 0.2% in China to 24.6% in 
Columbia (Odhiambo et al., 2009). 
 
The most recent data from phase three of the ISAAC study shows there to be a 
plateau (or even a slight decline in some countries) in AD prevalence in first world 
countries with the highest prevalence, but an increase in prevalence in the 
developing world (Williams et al., 2008). 
 
In Africa the highest prevalence of AD, according to the ISAAC phase three study, 
occurred in Morocco (23% prevalence in Casablanca and 20.5% prevalence in 
Marrakech), Ethiopia (19% prevalence in Addis Ababa), Guinea (18.8% prevalence 
in Condkry), and Ivory Coast (18.2% in Urban Cote d’Ivore) (Odhiambo et al., 2009). 
 
There are few studies on the prevalence of atopic dermatitis in South Africa. The 
ISAAC phase 1 study showed there to be an 8.3% prevalence rate of AD symptoms 
in schoolchildren aged 13 – 14 in Cape Town (Manjra et al., 2005). The ISAAC 
phase three study done 10 years later illustrated an increased prevalence rate of 
13.3% in Cape Town for children of the same age (Odhiambo et al., 2009). The 
prevalence of AD in the same age group of children in Polokwane in the ISAAC 
phase three study was 11.2%. No prevalence data is available for Gauteng.  
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While AD may affect patients of all ages, the peak age of onset is below 3 months 
(McNally et al., 1998). Both males and females are affected with studies showing a 
slight female predominance. Female to male ratios vary from 1:1 published by 
Turner et al in 1997 to 1.7:1 as reported by Larsson et al in 1994 (Ring et al., 2006). 
The reason for this trend is unknown. 
 
2.3 Pathogenesis 
Atopic dermatitis is a hypersensitive state, subject to genetic predisposition that 
manifests as a chronic inflammatory skin disorder (Sinclair et al., 2008). 
 
The aetiopathogenesis of atopic dermatitis is complex and multifactorial, involving 
an interplay of genetic, immune, neuroendocrine and environmental factors (Wolff 
and Fitzpatrick, 2008). Studies have implicated mutations in the filaggrin gene on 
chromosome 1q21 in European and Japanese patients leading to a defective barrier 
function in the stratum corneum. This leads to increased transepidermal water loss 
and enhanced penetration of environmental allergen resulting in increased 
inflammation and sensitivity (van den Oord and Sheikh, 2009). 
 
According to the 2005 South African Consensus Document on atopic eczema, 
exacerbating factors for episodes include colonisation by microbial agents 
especially staphylococcus aureus, certain environmental exposures, disruption of 
the cutaneous barrier, exposure to allergies and stress (Manjra et al., 2005). 
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2.4 Clinical features and symptoms 
Atopic dermatitis can be divided into acute, subacute and chronic stages. The acute 
stage is characterised by the presence of vesicles, crusts, exudate, oedema and 
erythema. In subacute dermatitis there are erythematous papules that may scale 
and become excoriated. The characteristic lesion of chronic AD is thickened 
plaques with lichenification (exaggeration of skin markings) with or without fibrotic 
papules (Wolff and Fitzpatrick, 2008). Lesions from all three stages may co-exist in 
the same patient. Dry, dull skin is seen in all stages of AD. 
 
Atopic dermatitis shows distinctive appearance and distribution of lesions at various 
ages. In infancy, it usually involves the face and extremities. In childhood and 
adulthood, the flexural areas are the most common sites. Chronic hand eczema is 
common in adults. However, generalised involvement may also occur at any age 
(Wolff and Fitzpatrick, 2008). 
 
Pruritis is the most common symptom experienced by patients and may be so 
severe that it leads to insomnia and secondary infection of open excoriations 
caused by scratching. Pruritis occurs throughout the day but is usually worse in the 
early evenings and at night (Bolognia et al., 2008). 
 
Secondary bacterial and viral infection may lead to pruritis, pain and scarring. 50% 
to 80% of patients with AD develop allergic rhinitis or asthma later in childhood 
(Wolff and Fitzpatrick, 2008). 
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2.5 Diagnostic criteria 
The Hanifin and Rajka criteria was the first diagnostic criteria for AD and was 
introduced in 1980 (Bolognia et al., 2008). It included 4 major and 23 minor criteria 
and proved to be too time-consuming and unmanageable in clinical settings 
(Samochocki and Dejewska, 2012). Various other diagnostic criteria have been 
proposed worldwide, however no ideal or uniform set of diagnostic criteria has been 
established. In South Africa, the most widely used is the reviewed criteria proposed 
by the South African childhood Atopic Eczema working group in 2005, i.e. 
Major criterion (must have): 
Pruritis  
Minor criteria (must have >=3 of the following): 
i. History of involvement of skin creases (flexural 
eczema) 
ii. History of generally dry skin in the past year 
iii. Personal history of asthma or hay fever 
iv. Onset under the age of 2 years 
v. Visible flexural eczema(Manjra et al., 2005) 
These diagnostic criteria were used in the current study. 
 
2.6 Management of Atopic Dermatitis 
The management of atopic dermatitis involves individualised care and is dependent 
on age of the patient, severity of disease and patient affordability amongst other 
factors. The approach involves: 
(i) General measures 
(ii) Adjuvant measures 
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(iii) Anti-inflammatory therapy 
 
(i)General measures                                                                                                  
 Since atopic dermatitis is a clinically hypersensitive state, various factors 
have been implicated in exacerbation of disease. Control of these 
aggravating factors significantly improves signs and symptoms of the 
dermatitis. 
 “Over bathing” has been associated with excessive loss of moisture from the 
cutaneous surface. Whilst patients are advised to bath regularly (once daily), 
over cleansing should be avoided (Manjra et al., 2005). 
 Patients are advised to avoid extremes of temperature as well as non-cotton 
fabrics on the skin as these may cause flares of eczema. 80% of infants with 
AD test positive for food allergy (Sampson, 1997a, Sampson, 1997b, 
Sampson and Ho, 1997). Certain foods have been implicated in aggravating 
allergies in patients, especially in young infants. Screening tests in the form 
of Fx 5e CAP followed by specific IgE CAP RAST for individual allergies, if 
the former is positive, is advised for young infants with chronic atopic 
dermatitis (Manjra et al., 2005). 
 Inhaled allergen screens may also be useful especially in patients with 
sensitivity to house dust mite. In these patients avoidance measures may 
significantly reduce symptoms. These measures include use of mite-
impermeable mattress covers and bedding, regular vacuuming, regular linen 
changes and 60 degree Celsius hot washing of bedding (Williams et al., 
1999). 
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(ii) Adjuvant measures 
 Soap substitutes are advised in place of ordinary soap. Options include pure 
glycerine soaps or other moisturising cleansers. Anti-bacterial cleansers 
should be avoided as they may lead to bacterial resistance (Manjra et al., 
2005). 
 Bleach baths in some severely affected individuals have been shown to aid 
with infection and inflammation from cutaneous flares. 
 Treatment of any infections should be instituted as soon as they occur. 
 Since xerosis of the skin is a salient feature of AD, the liberal use of 
emollients is recommended as first-line therapy. These need to be applied 
frequently during the day to relieve symptoms and signs of dryness, as they 
usually last only 6 hours on the skin. Different preparations are often required 
for different areas of the body and at different times of the year. Large 
quantities of emollient are usually required per week to maintain moisture 
and barrier function of the skin (Catherine Mack Correa and Nebus, 2012). 
 Antihistamines are often used for its effect on pruritis. However, because 
many mediators, other than histamine, are implicated in AD-induced pruritis, 
antihistamines may not be beneficial in all patients (Mollanazar et al., 2015).  
 
(iii) Anti-inflammatory therapies 
Topical corticosteroids: 
Intermittent topical corticosteroid usage to manage the disease is well documented 
(Abeck and Strom, 2000, Ellis et al., 2003). Mild to moderate potency preparations 
are usually used and applied once to twice daily until control is achieved followed 
by twice weekly applications thereafter to maintain the remission. The mildest agent 
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that can control the disease should be chosen. Potent and super potent topical 
steroids are sometimes required, but these should only be used for short periods of 
time (Thomas et al., 2002). 
 
Topical calcineurin inhibitors: 
Calcineurin inhibitors are immunomodulating, anti-inflammatory medications that 
have a rapid and sustained effect in treating both signs and symptoms of atopic 
dermatitis (Sunderkotter et al., 2006). In particular, it has been shown to relieve 
pruritis associated with diseases. It can be used alone or as an adjunctive measure 
together with topical steroids or systemic treatment in the management of acute or 
chronic AD. It has steroid sparing activity with very few adverse effects. It has been 
shown not only to prevent atrophy caused by steroids, but also to some extent to 
reverse mild steroid side effects (Kyllonen et al., 2004). It can be used for a longer 
period than topical steroids and on sensitive areas like the face and neck. Studies 
show that it can even be used safely on children as young as 3 years of age 
(Sunderkotter et al., 2006). Drawbacks to the treatment include the cost of the 
product and potential for cutaneous malignancy, albeit a rare event. Available 
agents in South Africa include Protopic and Elidel. 
 
Phototherapy: 
Both UVA and UVB either as monotherapy or as an adjunctive treatment has been 
shown to clinically improve AD (Patrizi et al., 2015). 
 
Systemic Rx:  
Oral anti-inflammatory immunomodulators are reserved for patients with severe  
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atopic dermatitis or recurrent or recalcitrant disease. 
 
Systemic corticosteroids: Long term side effects limit the continuous use of systemic 
corticosteroids. They have been shown to be effective in the short-term 
management of severe acute disease (Abeck and Strom, 2000), as well as for acute 
on chronic disease exacerbations. 
 
Azathioprine: Azathioprine is an immunosuppressive treatment that has been 
shown to be effective in the management of chronic atopic dermatitis in both adults 
and children. It presents a cheaper option to treatment than cyclosporine. 
Azathioprine is used more frequently in certain academic departments nationally. A 
randomised controlled trial in 2002 (Berth-Jones et al.) showed it to be effective in 
severe AD. Potential side effects  include nausea, vomiting, diarrhoea, pancreatitis, 
granulocytopaenia and rarely lymphoma to name a few (Wolverton, 2007). 
 
Methotrexate: Methotrexate has been used with some success in adults with severe 
AD (Hanifin et al., 2004). 
 
Cyclosporine: Cyclosporine affords rapid relief from severe disease, but it has many 
adverse effects and a high relapse rate following cessation of treatment. Schmitt et 
al found it to be an effective agent for severe disease in both adults and children 
(2007b). The tolerability of the drug was much better in children. Inaffordability of 
this very expensive drug is a worrying problem. 
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Mycophenolate mofetil, intravenous immunoglobulin, alpha-interferon: 
Mycophenolate mofetil is an immunosuppressive agent that exerts its mechanism 
of action by blocking the proliferation of T and B lymphocytes (Wolverton, 2007). It 
has therefore been studied for its use in AD. It has been shown to be effective and 
well tolerated with a good safety profile at an oral dose of 1g twice daily in adults 
with severe, recalcitrant disease (Neuber et al., 2000).  
 
Biologic agents: The advent of the biologic agent has issued in a new era not just 
in the treatment of dermatological disorders but medicine as a whole. Dupilumab is 
a monoclonal antibody that inhibits cytokines involved in the AD inflammatory 
pathway. While dupilumab is not yet available commercially, clinical trials show 
promising results (Beck et al., 2014). Investigation into other biologic agents is also 
currently being conducted. 
TREATMENT MODALITIES IN ATOPIC DERMATITIS 
 Therapy Level of evidence 
Topical  Emollients 
 Topical Corticosteroids 
 Topical calcineurin inhibitors 
 
2 
1 
1 
Local  UVB or UVA-UVB 
 Narrowband UVB 
 Oral PUVA 
 UVA 
 
1 
2 
1 
1 
Systemic  Systemic corticosteroids 
 Cyclosporine 
 Azathioprine 
 Mycophenolate mofetil 
 Methotrexate 
 Interferon 
 Immunoglobulin 
 Biologic agents 
 
2 
1 
1 
2 
2 
1 
2 
2-3 
Table 1.1 Summary of treatments available for Atopic Dermatitis 
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2.7 Quality of Life 
Advances in research in AD have changed our understanding of the disease at a 
molecular and genetic level (Barnes, 2010, Tang et al., 2012, Chen and Zhao, 
2013). This affords opportunities to translate these advances into the formulation of 
newer and better treatments. In the meantime, however, patients still experience a 
wide range of symptoms that affect their daily lives and the lives of their families. 
These symptoms range from mild to disabling. Some of them can be measured 
clinically, but others are more subtle occurring at a psychological level. 
Understanding the exact impact of the disorder is imperative in the management of 
these patients. 
 
The WHO defines Quality of Life as “the individual’s perception of their position in 
life in the context of culture and value systems in which they live and in relation to 
their goals, expectations, standards and concerns.” Many factors affect patients’ 
assessment of their quality of life. These include their personal and religious beliefs, 
physical health, psychological well-being, personal relationships, their home and 
work environment and independence level (The Whoqol, 1998). Q.O.L defines all 
aspects of a patient’s welfare and is not just limited to the effects on their medical 
health (Berzon et al., 1993).  
 
2.7.1 Quality of life in children with chronic disease 
Quantification of the impact of Quality of Life in patients with chronic diseases has 
become an important topic in both the developed and developing worlds. Much 
research has been conducted in children with various chronic disorders and this has 
shown the negative effects that the disease has on Health-Related Quality Of Life 
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(HRQOL) (Grootenhuis et al., 2007). Children with chronic diseases have been 
shown to have delayed developmental milestones when compared to other children 
(Suris et al., 2004). All aspects of the affected child’s life has been shown to be 
affected by a chronic condition. Besides physical and emotional effects, other areas 
of functioning that have been shown to be affected are cognitive and social aspects 
of a child’s life (Grootenhuis et al., 2007). These children have been shown to have 
higher levels of negative affect, school related problems, social withdrawal and poor 
peer relationships (Cheng et al., 2015).  
 
Research shows that children with chronic illnesses have a higher risk of developing 
anxiety-related disorders and learning difficulties compared to their healthier peers 
(Case et al., 2015, Cheng et al., 2015). A study of 152 children with chronic diseases 
in New Zealand showed that these children had an increased susceptibility towards 
developing depression and anxiety, hyperactivity, behavioural abnormalities and 
social problems (Case et al., 2015). 
 
2.7.2 Quality of life in children with chronic atopic dermatitis  
Many Q.O.L studies on patients with AD have been done (Aziah et al., 2002, Ben-
Gashir et al., 2002, Balkrishnan et al., 2003, Ben-Gashir, 2003, Ben-Gashir et al., 
2004, Chamlin et al., 2004, Beattie and Lewis-Jones, 2006a, McKenna and Doward, 
2008) , but to our knowledge, none have been conducted in South Africa. Most of 
the studies took place in the United Kingdom, the United States of America and 
Europe.  
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A Q.O.L study conducted in the UK compared the Q.O.L of children with chronic 
skin diseases and general medical conditions. It showed that AD was the leading 
dermatological cause of a decline in quality of life. When compared with chronic 
medical illnesses, atopic dermatitis had a decline in Q.O.L that equalled that seen 
in chronic renal disease, ranking second only to cerebral palsy. Asthma, cystic 
fibrosis, psoriasis, enuresis and epilepsy all had a lower decline in Q.O.L than AD 
(Beattie and Lewis-Jones, 2006b). 
 
Atopic dermatitis, together with  psoriasis and generalised pruritis have been shown 
to have a greater impact on Q.O.L than skin disorders such as acne, viral warts and 
basal cell carcinoma (Finlay and Khan, 1994). A 2002 South African study showed 
that most admissions to a tertiary dermatology centre in Cape Town were for 
extensive atopic dermatitis or psoriasis (Jessop et al.). 
 
AD in adolescence and in adulthood is associated with a predisposition towards the 
development of depression and anxiety later in life (Cheng et al., 2015). Pruritis and 
the feeling of being disfigured impart a psychological burden on patients leading to 
a major impact on their Q.O.L (Buske-Kirschbaum et al., 2001). Cosmetic 
consequences of AD can affect self-esteem, personal relationships and social 
acceptance (Humphreys and Humphreys, 1998). Chronic pruritis may play an 
important role in the development of sleep disturbances, anxiety, irritability and 
depression (Yang et al., 2010, Cheng et al., 2015). 
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2.7.3 Quality of life in patient’s families 
A large quality of life study in the UK showed that AD had a profound impact on 
Q.O.L on patients and their families. Two hundred and three infants and their 
families were studied. The most reported family symptoms included sleep loss, 
exhaustion and emotional distress (Beattie and Lewis-Jones, 2006a). 
 
Parents of affected children report social difficulties and feelings of worry, guilt, 
blame, and frustration due to their child’s skin disorder (Chamlin et al., 2004). 
There are no reported differences in the literature between the Q.O.L in boys and 
girls with AD. Younger atopic children had a more profound impact on their families 
Q.O.L (Ganemo et al., 2007). Caring for a child with AD is associated with greater 
sleep disturbance in parents than asthma (Moore et al., 2006). This correlated with 
increased anxiety and depression in mothers. 
 
The financial impact of atopic dermatitis was a major cause of a decrease in family 
Q.O.L. A study conducted in Italy showed that the average cost of a child’s AD was 
$1540 annually. Main expenses were due to special cleansing products, 
moisturizers and doctor visits (Ricci et al., 2006). The unmeasured expenses on the 
family unit will undoubtedly be related to the impact that the disease has on parents` 
work. Time taken off from work due to doctor visits, poor sleep, depression and 
anxiety affect work productivity, salary, bonuses and may prevent sufficient 
progress at work. Poor parent focus on personal ambitions and drive lead to parents 
of affected children stagnating in their careers. The financial impact to society is 
also significant with a US study estimating a cost of AD to the state to be $1 billion 
annually (Carroll et al., 2005). 
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Many studies conducted in Western, European and Asian countries confirmed that 
disease severity was correlated with family impact and Q.O.L of the affected child 
(Aziah et al., 2002, Ben-Gashir, 2003, Ben-Gashir et al., 2004, Chamlin et al., 2004, 
McKenna and Doward, 2008). Most studies also demonstrated the ability of 
caregivers to accurately assess the severity of their child’s AD with parental 
assessment strongly correlating with impact on Q.O.L of patients and their families 
(Ben-Gashir et al., 2002, Balkrishnan et al., 2003). 
 
2.7.4 Quality of Life Assessment in atopic dermatitis 
Multiple Q.O.L outcome measures are available to assess children with cutaneous 
disease (Lewis-Jones, 2006). For AD specifically, the dermatitis family impact (DFI) 
questionnaire (Lawson et al., 1998), the infants dermatitis Q.O.L index (IDQOL) 
(Lewis-Jones et al., 2001) and the parent’s index of Q.O.L in AD (DIQoL-AD) 
(McKenna et al., 2005) are tools which have been tested. These, however mostly 
focus on symptoms and functioning, with very few items dedicated to assess the 
emotional effects and broader impact of AD on the child and the family. 
 
2.8 The Childhood Atopic Dermatitis Impact Scale (CADIS) 
The Childhood Atopic Dermatitis Impact Scale (CADIS) is a validated QOL tool 
designed for children less than 6 years of age. It consists of 45 questions covering 
5 domains i.e. child’s symptoms, child’s limitation on behaviour and activity, family 
and social function, parent sleep and parent emotion. Evidence of its content and 
construct validity has been published (Chamlin et al., 2005) and test–retest reliability 
has been demonstrated (Chamlin et al., 2007). 
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2.9 Severity scoring systems for Atopic Dermatitis 
Approximately 20 different clinical scoring systems exist that measure the severity 
of AD. A systematic review published by Schmitt et al showed that only 3 of these 
measures showed adequate reliability and validity (2007a). These were the Patient- 
Oriented Eczema Measure (POEM), the Eczema Area and Severity Index (EASI) 
and the Severity Scoring system of AD (SCORAD). A variant of the SCORAD ie the 
objective SCORAD, which takes into consideration observer (clinician) based 
severity only, has also been validated and showed internal consistency (Angelova-
Fischer et al., 2005). 
 
For the purpose of the current study, two of the above scoring systems were chosen 
viz an objective scoring system in the form of the objective SCORAD and a 
subjective assessment of severity represented by the POEM. The inclusion of 2 
different outcome measures provides a more accurate measure of eczema severity. 
 
2.9.1 SCORAD 
The European Task force on Atopic dermatitis (ETFAD) developed the SCORAD 
index. It initially consisted of scores for extent of involvement, intensity and 
subjective symptoms (Pucci et al., 2005). The SCORAD index was later modified to 
exclude the subjective symptoms (Oranje et al., 2007). 
 
It measures the extent and severity of lesions of eczema. It has been shown to be 
one of the best instruments available to measure clinical signs of AD. It is valid, 
internally consistent and easily interpretable (Schram et al., 2012).  
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2.9.2 POEM 
Of the above 3 outcome measures, the POEM is the only one that is completely 
derived and assessed by the patient themselves. The POEM is a simple, easily 
understandable and validated tool to monitor disease severity in both children and 
adults with AD (Charman et al., 2004). It was initially developed to address the 
imbalance between patient and physician-based severity indices in AD research. It 
has been recommended in many reviews and national guidelines and has been 
used in outpatient departments, clinical trials and various studies. 
 
2.10 Conclusion of literature review 
Atopic Dermatitis is a chronic medical condition of childhood that has an immense 
impact on health-related Q.O.L in patients and their families, not only with regards 
to physical health, but emotional and mental health as well. Assessment of effect 
on Q.O.L can identify specific areas where intervention can be directed to improve 
Q.O.L of patients and their families, as well as to provide concrete data with which 
to motivate for funding of these interventions. 
 
Many studies have been done on the Q.O.L in patients with atopic dermatitis but, to 
our knowledge, there have been none conducted in South Africa. Most of these 
studies were conducted in the United States, Europe and Asia. The social, 
economic and environmental characteristics of South Africa greatly differ with these 
countries, rendering the need for a further study in our context. Furthermore, none 
of the studies encountered in the literature used the combination of SCORAD, 
POEM and CADIS to compare the severity of atopic dermatitis with Q.O.L.  
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Chapter 3 – METHODOLOGY  
In this chapter the methodology used in this research report will be presented. 
 
3.1 Study design 
This is a cross-sectional study. 
 
3.2 Location of the study 
This study was conducted at Chris Hani Baragwanath Academic Hospital in Soweto, 
Johannesburg. This hospital is the largest governmental medical institution in Africa. 
The study group was obtained from the Paediatric Dermatology Outpatient Clinic. 
 
3.3 Ethical clearance 
Ethical clearance for the proposed research was obtained from the University of 
Witwatersrand Human Research Ethics Committee (Clearance number M090305) 
(Appendix). Further permission was obtained from the hospital manager of CHBAH, 
the head of the Department of Dermatology and the managing specialist 
dermatologist at the Paediatric Dermatology Outpatient Clinic. 
 
Written informed consent was obtained from all caregivers for themselves as well 
as for each child participating in the research. 
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3.4 Study population 
Data from 381 children and their respective primary caregivers, who fulfilled the 
inclusion and exclusion criteria, was analysed. 
 
3.5 Sample selection 
Data was collected from 381 consecutive children aged < 6 years of age and their 
caregivers, who consented to participate in the study (within a 3 month period). They 
were all attendees at the dermatology paediatric outpatient department, receiving 
treatment there for AD. 
Inclusion criteria: 
 Children < 6 years old with a diagnosis of AD 
 Primary caregivers > 18 years of age 
Exclusion criteria: 
 Children in the study group who had any other chronic diseases that may 
impact on Q.O.L eg., chronic infections, autoimmune disorders 
 Children older than 6 years of age or 
 Primary caregiver < 18 years of age 
 Children who attended the clinic not accompanied by their primary caregiver, 
eg. friend, distant relative, sibling 
 
3.6 Timing of study 
The data collection was performed over a 3 month period. It commenced on 
Monday, 2 August 2010 and concluded on Thursday, 28 October 2010. 
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3.7 Sample size 
For the use of parametric statistical techniques, a minimum of 30 participants was 
necessary to achieve a statistical significance. Due to the central limit theorem, the 
larger the sample, the more normal the data will be. A sample size of 385 
participants would have yielded a power of 90 at 5% level of significance. Therefore 
to achieve statistically significant data with high power, the sample size aimed at 
was 385. However, over the 3 month period, data from only 381 patients were 
collected. 
 
3.8 Assessment tools 
Objective SCORAD  
Patients were assessed for disease severity using the modified objective SCORAD 
index. The site of involvement was also recorded. This objective severity 
assessment was conducted by a single-clinician, ie. the investigator, to prevent 
inter-observer bias.  
Regarding SCORAD: 
SCORAD (SCORingAD) index was developed by the European Task force on 
Atopic dermatitis (ETFAD). It initially consisted of scores for extent of involvement, 
intensity and subjective symptoms. The SCORAD index was later modified to 
exclude the subjective symptoms. It was thus then termed the objective SCORAD. 
Points are awarded as follows: 
1. Extent 
-Scored 0 to 100 depending on the percentage body surface area 
 involved 
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2. Intensity 
Each of 6 symptoms are graded 0 to 3 depending on intensity 
-erythema 
-oedema/papules 
-excoriations 
-lichenification 
-oozing/crusting 
-dryness 
All items were filled out on a SCORAD evaluation form (Appendix VII). The objective 
SCORAD index formula is Extent/5 + 7xIntensity/2. The maximum objective 
SCORAD score is thus 82 (plus an additional 10 bonus points for severe dermatitis 
of the face or hands). 
 
POEM  
Primary caregivers assess their child’s disease over the last week using the Patient- 
Oriented Eczema Measure (POEM). Seven signs/symptoms ie. dryness, flaking, 
itching, oozing, bleeding, cracking and disturbed sleep are rated according to a 5-
point scale,  depending on the number of days in the week that the child was 
affected by these. A maximum score of 28 can be assigned with a minimum score 
of 0. 
 
CADIS 
The CADIS is a Q.O.L questionnaire comprising 45 questions in 5 domains 
(Appendix IX). It is administered by the primary caregiver themselves and consists 
of statements regarding the child’s eczema and effect on child and family life over 
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the last four weeks. The primary caregiver notes how strongly they agree with each 
of the given statements by giving each statement a score of 0, 1, 2, 3 or 4 where 0 
means never, 1 denotes almost never, 2 sometimes, 3 correlating with an answer 
of often and 4 meaning always. 
 
3.9 Procedure  
3.9.1 Translation of questionnaires 
To ensure that our study sample was representative of the population attending 
Chris Hani Baragwanath Academic Hospital, it was important that the questionnaire 
was made available in isiZulu, which was the most commonly spoken language in 
the study population. The English questionnaire was thus translated into isiZulu and 
Sotho. English literate patients completed the English questionnaire and the isiZulu 
and Sotho speaking patients completed the translated questionnaire. 
 
3.9.2 Data collection 
Data was collected at the paediatric outpatient dermatology clinic that takes place 
every Monday and Thursday mornings. All attendees at the clinic, who fulfilled the 
inclusion and exclusion criteria during the three-month period, were invited to 
participate in the study. 
 
Before the study commenced, a research assistant was trained to administer and 
explain the measurement tools ie. POEM and CADIS, as well as to explain aspects 
regarding the nature of the research to the patients. She was able to communicate 
in English, isiZulu and Sotho. Consenting primary caregivers were provided with 
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patient information leaflets regarding the study in a language of their choice 
(English, isiZulu, Sotho) and consent was obtained in writing from the participating 
caregiver for themselves and their child/ward taking part in the study. Two separate 
consent forms were signed. (One for the primary caregiver and one for participating 
child). Thereafter they were provided with 2 self-administered questionnaires, that 
is the CADIS and the POEM (in a language of their choice). This was conducted in 
the clinic waiting room. 
 
Each primary caregiver was then interviewed in a private examination room by the 
researcher to obtain the required socioeconomic information including caregiver 
age, marital status, religion, highest educational level achieved, employment, 
residence and household income. The child was then examined and assessed by 
the researcher to determine severity of atopic dermatitis using the objective 
SCORAD index. 
 
3.10 Bias and limitation 
No bias existed in patient selection as the option of participation was given to all 
patients and caregivers attending the clinic during the 3 month period, who complied 
with the inclusion and exclusion criteria. 
Inter-observer bias was eliminated by a single-clinician (i.e. the researcher) 
performing the clinician assessment of disease severity using the objective 
SCORAD index. 
All patients were recruited from the Paediatric Dermatology Outpatient Clinic at 
Chris Hani Baragwanath Academic Hospital (CHBAH). This is a large referral 
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hospital and may therefore imply a referral bias towards increased disease severity. 
Mild cases were well represented in the study population, though.  
 
3.11 Statistical analysis 
The questionnaires were scored and all scores and demographic details were 
recorded in a database in excel format. It was then analysed statistically using SPPS 
(Statistical Packages for Social Sciences) version 13. 
 
Data description 
Continuous data was described by means and standard deviations as well as by 
the use of tables. 
Categorical data was described using frequency distribution, pie charts and bar 
graphs. 
 
Data analysis 
Bivariate analysis of categorical variables was done using Pearson’s Chi-Square 
Test (Fisher exact test where appropriate). 
To compare 2 continuous variables, the two independent T test was used. 
To correlate 2 continuous variables, the use of Pearson’s correlation and regression 
was used. 
To correlate more than 2 categories over a continuous variable, ANOVA (analysis 
of variables) was used.  
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Partial funding of the research was obtained from the Dermatology Society of South 
Africa and Galderma.  
All other costs were born by the researcher. 
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Chapter 4: RESULTS 
 
4.1 Introduction 
This chapter deals with the results of the statistical analyses of the data of quality of 
life in children less than 6 years old with atopic eczema and their families.  The first 
section presents the descriptive statistics of demographic profiles of patients in pie 
charts and bar graphs, and information related to Atopic Dermatitis in table format.  
 
The second section deals with the tests of significance for different indices used to 
assess the quality of life in children with atopic eczema and their families. SCORAD, 
CADIS and POEM are compared to each other using the Pearson Correlation 
Coefficient. CADIS and POEM scores are compared across the different categories 
of demographic details of patients. For two-category demographic details, two 
independent T-test is used and for more than two categories, Analysis of Variance 
(ANOVA) is used instead. To determine which of the domains of CADIS is mostly 
correlated to SCORAD or POEM, Pearson correlation coefficient is used. 
 
Prior to the two independent T-test or ANOVA, the test of normality is carried out to 
determine whether a parametric version or a non-parametric version will be used. If 
variables are normally distributed, the parametric tests (two independent T-test and 
ANOVA) are used; otherwise non-parametric tests (Mann-Whitney and Kruskal-
Wallis) are used.  
 
Histograms of scores in Appendix 1, serve to test normality. It can be seen that only 
the SCORAD score is highly skewed, compared to other scores. So, due to the 
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Central Limit Theorem, with the sample size of 381 far more than 30 as 
recommended, scores are considered as normally distributed. Therefore, 
parametric tests will be used for all of the scores except SCORAD, where non-
parametric tests will be used. 
 
All the analyses are carried out using the SPSS (Statistical Packages for Social 
Sciences) version 13. 
 
4.2 Descriptive Statistics 
4.2.1 Demographics 
4.2.1.1 Age Distribution of children 
The age distribution of the patients participating in this study is shown in the graph 
below. 
 
Figure 4.1 Age distribution of children 
Only a small number of children participating in the study were younger than one 
year of age (4.1%). Ninety-two patients (24.1%) were between the ages of 1 and 2 
27 (4.1%)
92 (24.1%)
105 (27.6%)
78 (20.5%)
79 (20.7%)
Age Distribution of children
Younger than or 1 year old 1.1 - 2 years
2.1 - 3 years 3.1 - 4 years
Older than 4 years
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years old; 105 (27.6%) were in the 2-3 year age group; 78 (20.5%) were between 
the ages of 3-4 years and 79 (20.7%) patients were older than 4 years of age. The 
majority of patients, almost 52% (51.7%) were 1-3 years of age. 
 
4.2.1.2 Gender Distribution of children 
The gender distribution of patients participating in this study is shown in the following 
graph (Figure 4.2). The majority (54.9%) of patients in the study were male and 
45.1% of study participants were female. 
 
   Figure 4.2 Gender distribution of children 
 
4.2.1.3 Caregiver Relationship and Distribution 
Figure 4.3 shows the distribution of caregivers of patients. 
In the study group 356 children (93.4%) had their mother as the primary caregiver.  
Twenty-one (5.5%) of the children’s primary caregiver was the father and only 1% 
(4 children) were cared for by a guardian. 
209 (54.9%)
172 (45.1%)
Gender Distribution of children
Male Female
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Figure 4.3 Frequency distributions of caregivers 
Ninety-nine per cent of patients (377) in the study were black, one per cent (4) of 
them were coloured. This correlated with the race of the primary caregivers. 
 
4.2.1.4 Distribution of age of Caregivers 
 
Figure 4.4. Distribution of the age groups of caregivers 
The pie chart (Figure 4.4) above shows the age distribution of the primary 
caregivers of children participating in the study.  
356 (93.4%)
21 (5.5%)
4 (1.0%)
Caregiver Distribution
Mum Dad Guardian
10 (2.6%)
193 (50.7%)
152 (39.9%)
25 (6.6%) 1 (0.3%)
Distribution of age of caregivers
Younger than or 20 years old 21 - 30 years
31 - 40 years 41 - 50 years
Older than 50 years
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The majority of caregivers (50.7%) were 20-30 years of age. One hundred and 
fifty-two caregivers (39.9%) were 31-40 years of age, 25 (6.6%) were in the 41-50 
year age group. Only 0.3% of caregivers fell in the older than 50 year age group 
and 2.6% were younger than 20 years of age. 
 
4.2.1.5 Distribution of Caregiver Education Level 
The pie chart below (Figure 4.5) illustrates the distribution of the education levels 
of the primary caregivers in the sample. 
 
 
Figure 4.5 Distribution of level of education of caregivers 
Only 3.1% of the caregivers in the sample had attained a university degree.110 
caregivers (28.9%) completed post matric studies. This included diploma and 
certificate training courses. 36% of caregivers matriculated with no further tertiary 
education and 122 caregivers (32%) did not matriculate.  
 
 
 
122 (32.0%)
137 (36.0%)
110 (28.9%)
12 (3.1%)
Distribution of caregiver education 
level
No matric
Matriculated
Non-degree post matriculated studies
University degree
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4.2.1.6 Caregiver Work Distribution 
 
Figure 4.6 Distribution of work of caregivers 
Figure 5.6 depicts the distribution of the types of work performed by the caregivers 
in the sample. 61.2% of the sample was unemployed. Skilled labour comprised only 
2.6% of the sample. 
 
4.2.1.7 Distribution of Religion  
Figure 5.7 shows the religious distribution of participants within the study. 
The vast majority (92%) of participants in the study were Christian. Twenty-five 
participants (6.6%) had no practising religion and only one patient (0.3%) was of 
the Islamic faith. 
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Figure 4.7 Frequency distribution of religion within the sample 
 
4.2.1.8 Distribution of Marital Status 
 
Figure 4.8 Frequency distribution of marital status of caregivers 
The graph above (Figure 4.8) indicates the marital status of caregivers of the 
children in the study. It clearly shows that the majority (76%) of caregivers of 
children with AD were single. Only eighty-seven (22.8%) caregivers were married. 
But Figure 5.9 below indicates that fifty percent cohabited with a partner.  
351 (92.1%)
1 (0.3%) 25 (6.6%) 4 (1.0%)
Distribution of religion in the sample
Christian Muslim No practising religion Other
291 (76.4%)
87 (22.8%)
3 (0.8%)
Distribution of marital status of 
caregivers
Single Married Widow
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4.2.1.9 Distribution of Cohabitation 
The graph below shows the cohabitation distribution of caregivers. 
 
Figure 4.9 Frequency distribution of cohabitation  
 
4.2.1.10 Areas of Residence 
The pie chart below shows the residence distribution of participants. 
 
Figure 4.10. Distributions of areas of residence 
A big majority (80.3%) of patients and their families in the study lived in Soweto and 
its surrounding suburbs, as seen in Figure 4.10. Thirty-seven (9.7%) lived less than 
30 kilometres from Soweto, 28 (7.0%) lived 31-70 kilometres from Soweto, 7 (2.0%) 
192 (50.4%)
189 (49.6%)
Partner in household
Yes No
306 (80.3%)
7 (2.0%)
37 (9.7%)28 (7.0%) 3 (0.8%)
Residence disribution of the 
sample
Soweto and its suburbs Unknown
<=30 km from Soweto 31 - 70 km from Soweto
More than 70 km from Soweto
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lived in unknown areas and 3 (0.8%) lived more than 70 kilometres away from 
Soweto.  
 
4.2.1.11 Income of Households 
The income of the participating children’s household is indicated in Figure 4.11. 
The majority of households, 210 (55.1%), earned less than or equal to R3000 a 
month. One hundred and eight (28.3%) made between R3000 and R6000 whilst 
23 (6.0%) earned between R6000 and R9000. Twenty (5.2%) households had a 
monthly income of between R9000 and R12 000 and 17 (4.5%) earned more than 
R12 000 a month. 
 
Figure 4.11 Distributions of income of households 
 
 
 
 
210 (55.1%)
108 (28.3%)
23 (6.0%)
20 (5.2%) 17 (4.5%)
Distribution of income of households
Less than or equal to R3000 R3001 - R6000
R6001 - R9000 R9001 - R12000
More than R12000
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4.2.2 Atopic Dermatitis Parameters 
Table 4.1 Descriptive statistics of children AD parameters 
 n Minimum Maximum 
Mean 
(SD) 
Median 
Corresponding 
items in CADIS 
SCORAD score 381 0 73 
13.49 
(14.92) 
8 
 
Total CADIS 381 0 174 
70.29 
(41.60) 
72 
 
Average 
Domain 1 - 
Child 
Symptoms 
381 0 4 
2.05 
(1.19) 
2 
1, 6, 9, 10, 12, 14, 
17 
Average 
Domain 2 - 
Child 
Limitations and 
Behaviour 
381 0 4 
1.34 
(0.94) 
1 
2, 21, 22, 24, 27, 
29, 34, 41, 43 
Average 
Domain 3 - 
Family and 
Social function 
381 0 4 
1.31 
(1.03) 
1.11 
4, 5, 7, 8, 11, 20, 
30, 4, 45 
Average 
Domain 4 - 
Parent Emotion 
381 0 4 
1.71 
(1.02) 
1.71 
3, 31, 36 
Average 
Domain 5 - 
Parent Sleep 
381 0 4 
1.04 
(1.12) 
1 
13, 15, 16, 18, 19, 
23, 25, 26, 28, 32, 
33, 35, 37, 38, 39, 
42, 44 
POEM 381 0 28 
10.60 
(6.90) 
8 
 
SD stands for Standard Deviation 
 
Table 4.1 shows descriptive statistics of the indices used to assess the impact and 
effects of severity of Atopic Dermatitis. It can be seen that all the five domains of 
Childhood Atopic Dermatitis Impact Scale (CADIS) have means ranging from 1 to 
2, with standard deviation of almost 1. This is an indication that the quality of life is 
assessed in a similar way in all the five domains. 
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4.2.2.1 Atopic dermatitis severity 
 
 
Figure 4.12 Severity distribution of Atopic Dermatitis in the sample using SCORAD 
 
 
 
 
Figure 4.13 Severity distribution of Atopic Dermatitis in the sample using POEM 
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Figure 4.12 depicts the distribution of severity within the sample population using 
the SCORAD index. 277 patients (72.7%) had mild disease (corresponding to a 
SCORAD score of <20), 76 patients (19.9%) had moderate disease (SCORAD 
score of 20-40) and 28 patients (7.3%) were severe (SCORAD score of >40). 
 
Figure 4.13 shows the severity distribution of the sample using the POEM. Using 
this index 39 patients (10.2%) were clear to almost clear of eczema (corresponding 
to a POEM score of 0-2), 125 patients (32.8%) were designated as mild disease 
(POEM score of 3-7), 135 patients (35.4%) had moderate disease (POEM score of 
8-16), 66 patients (17.3%) had severe disease (POEM score of 17-24) and 16 
patients (4.2%) scored as having very severe eczema (POEM score of 25-28).  
 
4.3. Comparisons 
 
Figure 4.14 Mean Severity Scoring of Atopic Dermatitis (SCORAD) index scores  
for each Childhood Atopic Dermatitis Impact Scale domain. 
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Figure 4.14 indicates that 277 patients (73%) are classified as having mild AD, 76 
(20%) with moderate AD, and 28 (7%) with severe AD. On average, the Child 
Symptom domain has the highest score in all the three groups of SCORAD severity. 
Parent Sleep domain has the lowest score in mild and moderate eczema, and Child 
Limitations and Behavior domain has the lowest score in the severe group. Score 
differences between mild and moderate groups are less than those between 
moderate and severe groups.  
 
Analysis of Variance (ANOVA) is used to determine whether the differences 
observed in all five CADIS domains, across the three groups of SCORAD severity 
index, are statistically significant. Results of the ANOVA are shown in Table 2 below. 
 
ANOVA is a statistical technique used to test whether scores of a numerical variable 
differ significantly across a categorical variable with more than two levels. The null 
hypothesis (H0) is that there is no difference and the alternative hypothesis (Ha) is 
the scores differ for at least two levels of the categorical variable. H0 is rejected, at 
5% significance level, if the p-value is less than 0.05, otherwise Ha is rejected 
instead.  
 
The p-values of 0.000<0.05 in Table 2 show that all the five domains significantly 
differ across the three groups. Bonferroni Post Hoc tests, Appendix 1, show that all 
pairwise comparisons are significant (P-value < 0.05), except child symptoms 
between moderate and severe groups. 
 
Total CADIS also differs significantly across the three groups of SCORAD. 
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Table 4.2 Comparison of CADIS domains and Total scores in children with mild, moderate and severe AD 
Domain 
Mild 
(n=277) 
Moderate 
(n=76) 
Severe 
(n=28) 
Number 
of items 
Range Test statistic P-value 
Child Symptoms 
1.72 
(1.13) 
2.74 
(0.90) 
3.30 
(0.80) 
7 0-4 F378, 2 = 50.3 0.000 
Child Limitations 
and Behavior 
1.14 
(0.89) 
1.71 
(0.83) 
2.25 
(0.90) 
9 0-4 F378, 2 = 28.8 0.000 
Family and Social 
function 
1.11 
(0.89) 
1.60 
(0.93) 
2.46 
(0.89) 
9 0-4 F378, 2 = 29.1 0.000 
Parent Emotion 
1.47 
(0.96) 
2.20 
(0.82) 
2.78 
(0.86) 
3 0-4 F378, 2 =38.7  0.000 
Parent Sleep 
0.79 
(1.00) 
1.48 
(1.15) 
2.32 
(0.96) 
17 0-4 F378, 2 = 36.7 0.000 
        
Total CADIS 
59.62 
(38.81) 
91.03 
(32.29) 
119.64 
(33.96) 
45 0-180 F378, 2 = 47.7 0.000 
Data are given as Mean (SD) 
 
To compare scores of CADIS and POEM across the different categories of 
demographic profiles of patients, independent samples T-test or ANOVA is carried 
out according to whether the demographic variable has two, or more than two 
categories. POEM is the only one that is significantly (p-value = 0.001) different 
across the five levels of child age, Table 4.3. The results of other demographic 
profiles are presented in Appendix 1.  
 
From the results of POEM in Table 4.3, we know that there are significant 
differences between the groups as a whole. Appendix 1 shows which groups 
differed from each other. It can be seen that the significant differences observed in 
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POEM across the different levels of child age, lie only between children younger 
than or 1 year old and each of the other groups (p-value < 0.05).  
Table 4.3 Comparison of CADIS and POEM across children’s age levels 
 
 
  n Range  Mean Median 
Test Statistic 
& P-value 
CADIS  
Younger than or 1 
year old 
27 13-144  
80,74 
(34.73) 
90  
1.1 - 2 years 92 7-159  
72,02 
(40.07) 
74 
F376, 4 = 0.854 
& 0.492 
2.1 - 3 years 105 0-162  
71,86 
(42.55) 
74  
3.1 - 4 years 78 0-155  
67,28 
(42.19) 
69  
Older than 4 years 79 5-174  
65,61 
(43.69) 
57  
         
POEM  
Younger than or 1 
year old 
27 1-28  
15,67 
(7.87) 
16  
1.1 - 2 years 92 0-27  
11,10 
(6.46) 
9 
F376, 4 = 4.894 
& 0.001 
2.1 - 3 years 105 0-28  
10,34 
(7.30) 
8  
3.1 - 4 years 78 0-27  
9,90 
(6.48) 
8  
Older than 4 years 79 0-28  
9,30 
(6.20) 
8  
 
 
Table 4.4 Comparison of CADIS across levels of education 
 
 
  n Range  Mean Median 
Test Statistic 
& P-value 
CADIS 
 
 
No matric 122 0-174  
72,29 
(43.34) 
83  
Matriculated 137 0-159  
63,97 
(38.63) 
64 
F377, 3 = 2.767 
& 0.042 
Non-degree post 
matriculated studies 
110 0-162  
70,25 
(42.79) 
68  
University degree 12 19-132  
61,67 
(35.20) 
55  
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Table 4.4 shows CADIS scores differed significantly across the caregivers level of 
education (P-value: 0042<0.05). A lower education was associated with a higher 
CADIS score. 
 
To compare two continuous variables, correlation coefficient is used. Correlation 
coefficient measures the strength and direction of a linear relationship between two 
variables on a scatterplot. If the scatterplot does not indicate there is at least 
somewhat of a linear relationship, the correlation does not mean much. As all our 
variables, except SCORAD are assumed to be normally distributed, Pearson’s 
correlation coefficient r is used. Spearman’s correlation coefficient rs is used for all 
correlations involving SCORAD. 
Rule of Thumb for interpreting the size of a correlation coefficient: 
Size of Correlation Interpretation 
0.90 to 1.00 (-0.90 to -1.00) 
Very strong positive (negative) 
correlation 
0.70 to 0.90 (-0.70 to -0.90) Strong positive (negative) correlation 
0.50 to 0.70 (-0.50 to -0.70) 
Moderate positive (negative) 
correlation 
0.30 to 0.50 (-0.30 to -0.50) Weak positive (negative) correlation 
0.00 to 0.30 (0.00 to -0.30) Negligible correlation 
 
Figure 4.15 comprises three plot charts and depicts the correlations between 
SCORAD, CADIS and POEM. There is a weak positive correlation (0.423) between 
CADIS and SCORAD, while the correlations of POEM with SCORAD and CADIS 
are moderate positive (0.700 and 0.672). Among the CADIS domains, Child 
Symptoms is mostly correlated to POEM (r = 0.67), Figure 4.16, and to SCORAD (r 
= 0.46), Figure 4.17. 
 
All correlation coefficients are highly significant (p-value 0.000 < 0.05).  
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rs = 0.423  (p-value = 0.000)                    
 
rs = 0.700  (p-value = 0.000) 
 
rs = 0.672  (p-value = 0.000) 
Figure 4.15 Correlations between SCORAD, POEM and CADIS 
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Figure 4.16 Correlations between CADIS domains and POEM   
   r = 0.673 (p-value = 0.000)                         r = 0.567 (p-value = 0.000)  
   
   r = 0.529 (p-value = 0.000)                         r = 0.636 (p-value = 0.000) 
   
     r = 0.484 (p-value = 0.000) 
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        Figure 4.17 Correlations between SCORAD and CADIS domains 
 r = 0.464 (p-value = 0.000)                       r = 0.383 (p-value = 0.000) 
    
    r = 0.349 (p-value = 0.000)                               r = 0.423 (p-value = 0.000) 
      
r= 0.388 (p-value = 0.000) 
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Chapter 5: DISCUSSION 
 
In chapter 5, the results obtained from the study will be discussed. The limitations 
of the study and recommendations for future studies will also be discussed. 
 
5.1 Demographics 
In this study, the Q.O.L of 381 children were evaluated using the CADIS. To our 
knowledge, no other study using this tool has been conducted in South Africa. 
Previous studies using this assessment tool sampled a smaller number of patients 
(Chamlin et al., 2007). 
 
Fifty four point nine percent of patients were male. Most studies on atopic dermatitis 
show that it affects males and females equally with a slight female predominance. 
This was not the case in the present study. 
 
Only children less than or equal to 6 years of age were invited to participate in the 
study. This age group was chosen as younger children are more dependent on their 
parents and family members for their primary care and as such, health related 
problems in these children will impact greatly on the quality of life of the family unit 
as a whole. The mean age of the children participating in the present study was 
3.07 years with 51.7% of the sample being between the ages of 1 and 3 years. Only 
4.1 % of the study population was less than or equal to 1 year of age. Age was a 
significant contributing demographic factor in the study. A significant difference in 
AD severity and QOL scores existed for children 1 year and younger (p<0.05). This 
group had proportionately higher POEM scores denoting higher perceived severity 
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of their disease and had higher CADIS scores showing a worse quality of life than 
their older counterparts.  The mean and median CADIS scores showed a decline 
with increasing age illustrating the improvement of quality of life in the patient and 
their families as the children grew older. This finding was in keeping with other 
research that demonstrates AD to have a more profound effect on the QOL in 
younger patients (Ganemo et al., 2007). 
 
Of the primary caregivers, 93.4% were the mothers of the patients and the majority 
of the sample was black (99%). Ninety two per cent of patients followed the Christian 
faith. None of these demographic factors showed to affect the QOL scores.  
 
The mean age of the primary caregiver was 30.4 years with most caregivers (50.7%) 
being between the ages of 20 and 30 years. The low education level of the sample 
was evidenced in the data which showed that only 3.1% of the primary caregivers 
in the study group attained a tertiary degree. Thirty six per cent of participants 
attained matric qualification only with no further studies and 32% of caregivers did 
not complete their secondary school education at all. This translated into a 
staggering 61.2% unemployment rate amongst the primary caregivers. A majority 
of 55.1% of the sample reported a household income of less than R 3000 per month. 
This younger age of most caregivers, low income and education levels and high 
rate of unemployment brings to the fore the burden that families affected with AD 
will face in South Africa. The financial impact of atopic dermatitis has been shown 
previously to be a major cause of decrease in family Q.O.L. A study conducted in 
Italy showed that the average cost of a child’s AD was $1540 annually (Ricci et al., 
2006) . Similar studies have not been conducted in South Africa, so an exact rand 
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value cannot be placed on this cost. Main expenses in the Italian study were due to 
moisturisers, special cleaning products and doctor visits (Ricci et al., 2006). In the 
current sample, as all patients were being cared for at a state facility, these costs 
were not the burden of the family to bare. However, parents still require to take time 
off from work for various reasons. This may be due to doctor visits, lack of sleep 
during periods of disease flares and psychological problems such as stress and 
anxiety. This has a negative impact on parent earnings.  
 
Caregiver education level was a significant factor predicting QOL in the present 
study, with a lower education level being associated with a greater decline in QOL 
scores (p 0042<0.05). All other demographic factors were shown not to be a 
significant factor affecting QOL in the present study. 
 
Poor socioeconomic circumstances have been shown to affect psychosocial 
development of children (Chandan and Richter, 2009; Earls et al, 2008). It is 
therefore very important to determine socioeconomic status when assessing quality 
of life. All children and primary caregivers were chosen from the Paediatric 
Dermatology Outpatient Clinic at Chris Hani Baragwanath Academic Hospital, 
which is traditionally renowned for servicing a highly underprivileged community 
with a poor socioeconomic background. 80.3% of the sample resided within Soweto 
and its suburbs. 
   
Seventy six per cent of caregivers were single and only 50% of caregivers 
cohabitated with their partner. 
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5.2 Atopic Dermatitis severity 
The objective SCORAD was used as the physician’s measure of severity of AD. 
72.7% of patients had mild disease, 19.9% had moderate disease and 7.3% were 
designated as having severe disease. The POEM is a self-administered tool and 
accounts only for subjective symptoms of AD from the point of view of the 
patient/caregiver. Using this index 10.2% of patients were clear to almost clear of 
eczema, 32.8% were designated as having mild disease, 35.4% as moderate 
disease, 17.3% as severe disease and 4.2% of patients had very severe eczema. 
The mean SCORAD was 13.49 (falling within the mild category) and the mean 
POEM was 10.60 (falling within the moderate category). These figures clearly show 
the disparity between the objective and subjective severity scoring systems in atopic 
eczema. The patient’s perceptions of severity was demonstrably higher than the 
physician`s objective severity assessment. 
 
5.3 Quality of life  
The degree of impairment in QOL was proportional to the severity of AD as 
measured by SCORAD and POEM ie. the CADIS scores were higher in moderate 
AD than in mild AD and higher in severe AD than in moderate AD. Many previous 
studies corroborate this finding of the increased effect on QOL with increasing 
severity of the atopic eczema (Ben-Gashir et al., 2004, Kim et al., 2012). A greater 
correlation existed between POEM and CADIS than with the objective SCORAD 
and CADIS, meaning that patients perceived disease severity was more in tune with 
the impairment in quality of life than the physician’s assessment of disease severity. 
No precedent exists for this finding as these scores were never previously compared 
to QOL in a single study. 
55 | P a g e  
 
The individual domain scores and the total CADIS scores showed a greater 
difference between moderate and severe disease than it did between mild and 
moderate disease, demonstrating a much greater impairment in quality of life in 
children with severe atopic dermatitis. The domain of child symptoms showed less 
of a disparity between the moderate and severe groups. Even though the scores for 
child symptoms did increase from the moderate to severe AD group, the difference 
was much less than was present in the other domains. This shows that the 
impairment in QOL imparted by the child’s symptoms, while more in severe than 
moderate disease, does not show as much disparity between the severity groups 
than the other domains. As the disease increases in severity the other domains 
particularly those that impact the family seem to be affected more dramatically, 
demonstrating the severe decline in QOL within the family as whole in severe 
disease. 
  
Child’s Symptoms was still the QOL measure most affected in all 3 severity groups. 
Parent sleep was the least affected domain in mild and moderate AD but increased 
significantly in severe disease. Parent emotion and child symptoms domains were 
the most affected in severe disease. 
  
5.4 Limitations of the research 
 All patients were recruited from the Paediatric Outpatient Department at 
Chris Hani Baragwanath Academic hospital. This may impart some referral 
bias with patient’s caregivers perceiving a greater severity of their child’s 
disease based on the fact that they attend a tertiary referral centre. 
 The study was a cross-sectional one with a once off QOL and severity 
assessment being performed for each child. Comparison data was not 
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attained to assess QOL in the same patients over a period of time, which 
could add an important dimension to the study.  
 The 45-item CADIS proved to be time consuming and difficult to perform in 
a busy clinic such as is the case at Chris Hani Baragwanath Academic 
Hospital. 
 The results of this study may not be used to draw generalized conclusions to 
children in all age groups, as the current research included children in only a 
very narrow age range. 
 
5.5 Relevance to clinical practice and recommendations based on results 
Quality of life assessment is an important tool in fully understanding the impact of 
atopic dermatitis. The current study showed that the physician’s severity 
assessment of AD did not correlate as well as caregiver assessment to adequately 
predict the impairment in QOL in affected children. And neither severity assessment 
accounts for the decrease in quality of life experienced by the patient’s family. QOL 
measurement tools are unfortunately not routinely performed at a dermatology clinic 
level due to high patient numbers and due to the fact that these assessments are 
time consuming. The importance of QOL, as demonstrated by the current study, 
obviates a need for a standard, simple, routine QOL tool to be introduced into the 
paediatric dermatology clinics. This will provide invaluable information and insight 
into patient disease severity and family impact of the disease. 
 
Atopic Dermatitis has been shown to have a negative impact on QOL of children 
suffering with from disease with increased severity correlating with a worse impact 
on physical and psychosocial functioning. It is, therefore, evident that services 
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offered at the paediatric dermatology clinics should not only concentrate on the 
medical management of the disease. There is a need for a multi-disciplinary 
approach that meets medical, social and psychological needs of the patient. This 
may decrease stress and anxiety experienced by the patients, which in turn will 
support a more favourable therapeutic outcome. Intervention aimed at all aspects 
of functioning may be essential to ensure children attain a smooth transition into 
adolescence and adulthood. These interventions should not be based only at large 
referral clinics but need to be extended to local clinics, communities and the school 
environment. 
 
In addition, programmes should be extended to meet the needs of caregivers and 
families of affected children. Better education needs to be provided to family 
members about the affected child’s condition and in-depth counselling should be 
performed regarding topical steroid and emollient usage, prevention of infection, 
compliance to treatment, avoidance of trigger factors and grooming practices. 
 
The financial burden on families and effect on psychosocial functioning of the 
primary caregiver has been well documented and has also been demonstrated in 
the current research. A need therefore exists for the establishment of Atopic 
Dermatitis support groups, care dependency grants for AD and psychologist and 
social worker assessment of severely affected families. 
 
Parent workplace intervention by means of employer education and counselling 
may foster greater understanding of family needs. Allowing for special family 
responsibility leave and flexible work hours are some changes that can be 
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negotiated for parents at their workplace to assist parents with the care of their 
atopic children. This will help to alleviate stress and anxiety for parents at the 
workplace, resulting in a more productive working environment. 
 
Improving community awareness of AD needs to be pioneered to decrease stigmata 
associated with the disease. This can be achieved by performing school outreach 
programmes, awareness days at school, as well as consultation with educators and 
community leaders. 
 
5.6 Recommendations for future research 
Research has shown that children suffering from AD have a lower quality of life. 
 Further studies using the same tools should be performed on the same 
sample at different times during the disease course to demonstrate the 
change in QOL in children as the severity of their disease changes and as 
symptoms and signs evolve over time. 
 Studies that include children within a broader age range would be useful to 
assess the impact of AD at all stages of development. 
 A prospective study of QOL would be interesting to demonstrate the changes 
in disease severity and QOL as children graduate to adolescence and then 
adulthood. 
 The creation and validation of a reliable, simple QOL questionnaire for a 
South African setting needs to be developed. This tool should be quick and 
easy to perform routinely in busy outpatient clinics. 
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This study is important for further research that would be of benefit to developing 
countries such as South Africa. Limited research using validated QOL measures 
have been done in the field of atopic dermatitis worldwide and, to our knowledge, 
none have been performed in South Africa, leading to a large gap in the literature 
on this topic. The results of this study will contribute to the development of a more 
comprehensive management programme for children with atopic dermatitis.  
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Chapter 6: CONCLUSION 
 
Recent studies show that the prevalence of atopic dermatitis in the developing world 
is increasing (Odhiambo et al., 2009). It has become a major cause of chronic illness 
in childhood (Madhok et al., 2015). Quality of Life measures has therefore become 
an important medical outcome to consider in affected children and their families. 
The aim of the research was to evaluate the Q.O.L of children < 6 with atopic 
eczema and their families in a South African setting. The Childhood Atopic 
Dermatitis Impact Scale was the measurement tool used. Three hundred and eighty 
one subjects and their caregivers were assessed. 
 
The CADIS has been shown to be valid and reliable and has been used in previous 
research in children < 6 with AD. For this study, the questionnaires were translated 
into isiZulu and Sotho. 
 
The results indicated that atopic dermatitis has a negative impact on the quality of 
life of affected children and their families. The degree of impairment of quality of life 
increased with increasing disease severity. This finding supports previous studies 
that demonstrated similar findings (Ben-Gashir et al., 2004, Kim et al., 2012). The 
greatest impact on QOL in all severity groups was in the area of the affected child’s 
symptoms. The family QOL was affected more as the disease severity increased. A 
relationship was established between QOL and patient age, where a higher 
impairment in child and family QOL existed for children less than 1 year of age. It 
was also associated with lower caregiver education level. The QOL measure 
showed a higher correlation to the caregiver assessment of severity than to the 
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physician’s assessment, suggesting that patient derived outcome measures should 
be the most essential measure in adequately assessing disease severity.  As shown 
in the current research, the POEM is simple, quick and easy to perform, making it 
ideal to use in a clinic setting as a marker of both severity of disease and QOL.  
 
There is a need for further research of children in South Africa with AD. This is 
essential to identify effective interventions to improve disease severity and Q.O.L in 
patients and their families. Some interventions that may help to alleviate the burden 
of disease include parent education, psychological counselling of patients and 
families, the formulation of AD support groups, financial assistance to affected 
families in the form of care dependency grants and outreach programmes to 
schools, workplaces and the community to improve awareness of AD to foster better 
understanding of elements of the disease and the effects it has on patients and their 
families. These interventions could help in the development of atopic children into 
healthy adults capable of effective family, community and social interaction. 
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Appendix Ia 
 
 Histograms of Atopic Dermatitis 
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Appendix Ib 
 
Pairwise comparisons of CADIS domains across SCORAD severity 
classification 
Post Hoc Tests  
Multiple Comparisons  
Bonferroni  
Dependent Variable 
(I) SCORAD 
interpretation 
(J) SCORAD 
interpretation 
Mean 
Difference (I-J) 
Std. 
Error 
P-
value 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Average Domain 1 - Child 
symptoms 
Mild 
Moderate -1,057(*) ,138 ,000 -1,39 -,73 
Severe -1,576(*) ,211 ,000 -2,08 -1,07 
Moderate 
Mild 1,057(*) ,138 ,000 ,73 1,39 
Severe -,519 ,235 ,083 -1,08 ,05 
Severe 
Mild 1,576(*) ,211 ,000 1,07 2,08 
Moderate ,519 ,235 ,083 -,05 1,08 
Average Domain 2 - Child 
limitations and behaviour 
Mild 
Moderate -,568(*) ,113 ,000 -,84 -,29 
Severe -1,105(*) ,174 ,000 -1,52 -,69 
Moderate 
Mild ,568(*) ,113 ,000 ,29 ,84 
Severe -,537(*) ,194 ,017 -1,00 -,07 
Severe 
Mild 1,105(*) ,174 ,000 ,69 1,52 
Moderate ,537(*) ,194 ,017 ,07 1,00 
Average Domain 3 - Family 
and social function 
Mild 
Moderate -,48621(*) ,12508 ,000 -,7870 -,1854 
Severe -1,35029(*) ,19154 ,000 -1,8109 -,8897 
Moderate 
Mild ,48621(*) ,12508 ,000 ,1854 ,7870 
Severe -,86408(*) ,21353 ,000 -1,3776 -,3506 
Severe 
Mild 1,35029(*) ,19154 ,000 ,8897 1,8109 
Moderate ,86408(*) ,21353 ,000 ,3506 1,3776 
Average Domain 4 - Parent 
emotion 
Mild 
Moderate -,73272(*) ,12013 ,000 -1,0216 -,4438 
Severe -1,31215(*) ,18396 ,000 -1,7545 -,8698 
Moderate 
Mild ,73272(*) ,12013 ,000 ,4438 1,0216 
Severe -,57944(*) ,20508 ,015 -1,0726 -,0863 
Severe 
Mild 1,31215(*) ,18396 ,000 ,8698 1,7545 
Moderate ,57944(*) ,20508 ,015 ,0863 1,0726 
Average Domain 5 - Parent 
sleep 
Mild 
Moderate -,689(*) ,134 ,000 -1,01 -,37 
Severe -1,533(*) ,205 ,000 -2,03 -1,04 
Moderate 
Mild ,689(*) ,134 ,000 ,37 1,01 
Severe -,844(*) ,228 ,001 -1,39 -,30 
Severe 
Mild 1,533(*) ,205 ,000 1,04 2,03 
Moderate ,844(*) ,228 ,001 ,30 1,39 
* The mean difference is significant at the .05 level. 
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Appendix Ic  
 
Pairwise comparisons of CADIS and POEM across children’s age levels 
 
Post Hoc Tests  
Multiple Comparisons  
Bonferroni  
Dependent 
Variable 
(I) Age of child (J) Age of child 
Mean 
Difference (I-J) 
Std. 
Error 
Sig. 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
POEM 
Younger than or 
1 year old 
1.1 - 2 years 4,569(*) 1,479 ,022 ,39 8,75 
2.1 - 3 years 5,324(*) 1,458 ,003 1,21 9,44 
3.1 - 4 years 5,769(*) 1,509 ,002 1,51 10,03 
Older than 4 
years 
6,363(*) 1,507 ,000 2,11 10,62 
1.1 - 2 years 
Younger than or 
1 year old 
-4,569(*) 1,479 ,022 -8,75 -,39 
2.1 - 3 years ,755 ,965 1,000 -1,97 3,48 
3.1 - 4 years 1,200 1,040 1,000 -1,74 4,14 
Older than 4 
years 
1,794 1,037 ,843 -1,13 4,72 
2.1 - 3 years 
Younger than or 
1 year old 
-5,324(*) 1,458 ,003 -9,44 -1,21 
1.1 - 2 years -,755 ,965 1,000 -3,48 1,97 
3.1 - 4 years ,445 1,010 1,000 -2,41 3,30 
Older than 4 
years 
1,039 1,007 1,000 -1,80 3,88 
3.1 - 4 years 
Younger than or 
1 year old 
-5,769(*) 1,509 ,002 -10,03 -1,51 
1.1 - 2 years -1,200 1,040 1,000 -4,14 1,74 
2.1 - 3 years -,445 1,010 1,000 -3,30 2,41 
Older than 4 
years 
,594 1,079 1,000 -2,45 3,64 
Older than 4 
years 
Younger than or 
1 year old 
-6,363(*) 1,507 ,000 -10,62 -2,11 
1.1 - 2 years -1,794 1,037 ,843 -4,72 1,13 
2.1 - 3 years -1,039 1,007 1,000 -3,88 1,80 
3.1 - 4 years -,594 1,079 1,000 -3,64 2,45 
* The mean difference is significant at the .05 level. 
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Appendix Id  
 
Comparisons of CADIS and POEM across other demographic profiles 
 
Independent Samples Test across Gender 
  
Levene's Test 
for Equality of 
Variances 
t-test for Equality of Means 
F Sig. T df 
Sig. (2-
tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
CADIS 
Equal 
variances 
assumed 
,050 ,823 1,073 379 ,284 4,595 4,282 -3,824 13,014 
Equal 
variances 
not 
assumed 
  1,072 364,009 ,284 4,595 4,285 -3,831 13,021 
POEM 
Equal 
variances 
assumed 
6,349 ,012 1,277 379 ,202 ,906 ,709 -,489 2,301 
Equal 
variances 
not 
assumed 
  1,296 378,158 ,196 ,906 ,699 -,469 2,281 
 
 
 
ANOVA across Income 
  Sum of Squares df Mean Square F Sig. 
CADIS 
Between Groups 2072,030 4 518,008 ,301 ,877 
Within Groups 642524,015 373 1722,584   
Total 644596,045 377    
POEM 
Between Groups 39,863 4 9,966 ,208 ,934 
Within Groups 17891,780 373 47,967   
Total 17931,643 377    
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ANOVA across level of education 
  Sum of Squares df Mean Square F Sig. 
CADIS 
Between Groups 14165,194 3 4721,731 2,767 ,042 
Within Groups 643393,882 377 1706,615   
Total 657559,076 380    
POEM 
Between Groups 190,435 3 63,478 1,339 ,261 
Within Groups 17877,318 377 47,420   
Total 18067,753 380    
 
 
 
Independent Samples Test across partner in household 
  
Levene's Test 
for Equality of 
Variances 
t-test for Equality of Means 
F Sig. T df 
Sig. (2-
tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
CADIS 
Equal 
variances 
assumed 
,184 ,668 ,122 379 ,903 ,520 4,268 -7,872 8,912 
Equal 
variances 
not assumed 
  ,122 378,611 ,903 ,520 4,269 -7,873 8,913 
POEM 
Equal 
variances 
assumed 
,879 ,349 
-
,496 
379 ,620 -,351 ,707 -1,741 1,040 
Equal 
variances 
not assumed 
  -
,496 
377,553 ,620 -,351 ,708 -1,742 1,041 
 
 
ANOVA across level of age of caregiver 
  Sum of Squares df Mean Square F Sig. 
CADIS 
Between Groups 4302.395 4 1075.599 0.619 0.649 
Within Groups 653256.7 376 1737.385   
Total 657559.1 380    
POEM 
Between Groups 341.887 4 85.472 1,813 0.126 
Within Groups 17725.867 376 47.143   
Total 18067.753 380    
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Appendix III: Informed consent- Patient  
 
INFORMED CONSENT FOR PATIENT 
 
I,……………………………………………………(full name of parent/guardian) agree 
on behalf my child/ward……………………………(full name of child/ward) to 
participate in the study entitled:  Quality of life study on children with atopic 
dermatitis: as assessment of the impact and effects of severity of atopic dermatitis 
on affected patients and their families, which will be conducted at Chris Hani 
Baragwanath Hospital. 
 
I have been informed by my study doctor about the nature and conduct of this 
study. I have also received, read and understood the patient information leaflet. I 
understand that participation in this study is voluntary and my child will not be 
discriminated against if I decide not to participate in this study. I also understand 
that I will not be paid for my child to participate in this study. I am aware that the 
results of the study will be anonymously processed into a study report. I agree for 
the collected data to be processed in a computerized system. 
 
I agree to my child being examined by his/her doctor and recording the findings. I 
have had sufficient opportunity to ask questions and declare that I am prepared for 
my child to participate in the study. 
 
Participant 
Signature of parent/guardian or mark/thumbprint: 
Printed name: 
Date: 
Time: 
 
I,…………………………………………., herewith confirm that the above participant 
has been fully informed about the nature, conduct and risks of the above study. 
 
Investigator 
Signature of investigator: 
Printed name: 
Date: 
Time: 
 
Witness 
Signature of witness: 
Printed name: 
Date: 
Time: 
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Appendix IV: Informed Consent- Parent/Guardian 
 
INFORMED CONSENT FOR PARENT/GUARDIAN 
 
I,……………………………………………………(full name of parent/guardian), 
parent/guardian of……………………………(full name of child/ward) agree to 
participate in the study entitled:  Quality of life study on children with atopic 
dermatitis: as assessment of the impact and effects of severity of atopic dermatitis 
on affected patients and their families, which will be conducted at Chris Hani 
Baragwanath Hospital. 
 
I have been informed by my study doctor about the nature and conduct of this 
study. I have also received, read and understood the patient information leaflet. I 
understand that participation in this study is voluntary and I or my child will not be 
discriminated against if I decide not to participate in this study. I also understand 
that I will not be paid to participate in this study. I am aware that the results of the 
study will be anonymously processed into a study report. I agree for the collected 
data to be processed in a computerized system. 
 
I agree to fill in the self-administered questionnaire. I have had sufficient 
opportunity to ask questions and declare that I am prepared for myself and my 
child to participate in the study. 
 
Participant 
Signature of parent/guardian or mark/thumbprint: 
Printed name: 
Date: 
Time: 
 
I,…………………………………………., herewith confirm that the above participant 
has been fully informed about the nature, conduct and risks of the above study. 
 
Investigator 
Signature of investigator: 
Printed name: 
Date: 
Time: 
 
Witness 
Signature of witness: 
Printed name: 
Date: 
Time: 
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Appendix V: Information Sheet- Patient 
 
PARTICIPANT INFORMATION LEAFLET FOR PATIENT 
STUDY NUMBER:       DATE: 
PATIENT NUMBER:  
 
TITLE OF THE STUDY: AN ASSESSMENT OF THE IMPACT OF SEVERITY OF 
ATOPIC DERMATITIS ON THE QUALITY OF LIFE OF AFFECTED PATIENTS 
AND THEIR FAMILES. 
STUDY INVESTIGATOR: Dr K Govender 
INSTITUTION: University of the Witwatersrand 
 
This document may contain words that you do not understand. Please ask the 
study doctor to explain any words or information that you do not clearly 
understand. You may take home an unsigned copy of this information leaflet and 
consent form to think about or discuss with your family before making your 
decision as to whether to allow your child/ward to participate in this study or not. 
Before you agree for your child/ward to participate, it is important that you 
understand the purpose of the study and the procedures involved. This 
information leaflet is to help you to decide if you want your child/ward to participate 
in this study. If you have any questions, do not hesitate to ask me. If you agree for 
your child to participate, you will be asked to sign a consent form to confirm you 
understand the study procedure and that you are willing for your child to 
participate. 
 
We are inviting your child to participate in a research study conducted at the 
pediatric dermatology outpatient clinic at Chris Hani Baragwanath Hospital. 
 
Your child has been diagnosed with atopic dermatitis. Atopic dermatitis is a 
chronic itchy skin problem that can affect any age group but usually occurs in 
children. It is not contagious. There may be a family history of eczema, asthma or 
runny nose. In this study, we want to learn how atopic dermatitis affects the daily 
activities and quality of life in your child, your family and yourself.  
 
Participation in this study is being offered to all children less than 6 years old with 
atopic dermatitis and their parent/guardian. At your appointment, your child will be 
examined and the findings will be recorded in his/her file and on anonymous 
record sheets for the study. After that you will be asked to complete a 
questionnaire which is confidential. The study will be conducted over 3 months. 
Your child will only be examined for the purpose of the study on one visit, 
therefore the total time required for your participation and that of your child in this 
study will be a maximum of 1 hour. 
 
Participation in this study is voluntary. Your child/ward will not be discriminated 
against if you decide for him/her not to participate in this study. Your child/ward will 
still receive all his/her medication. Your child/ward will not be harmed in any way 
during the study. There are no risks in this study. No medication will be tested on 
your child/ward. Your child will still continue with his/her normal treatment. If your 
child`s treatment is changed, it is because the state of his/her skin condition has 
changed and is not related to the study. There are no direct benefits to you or your 
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child/ward for participating in this study. You will not be paid for taking part in the 
study. 
 
All information obtained during the course of this study, including hospital records, 
personal data and research data will be strictly confidential. Data that may be 
reported in scientific journals will not include any information that identifies your 
child as a clinical participant in this study. The information might also be inspected 
by the University of the Witwatersrand, Human Research Committee. 
 
This study protocol has been submitted to the University of the Witwatersrand, 
Human Ethics Committee. If you require any information regarding your rights as a 
research participant, or have any complaints regarding this research, you may 
contact Prof Cleaton Jones, Chairperson of the University of the Witwatersrand, 
Human Research Ethics Committee established to help protect the rights of 
research participants at 011-717 2229. 
 
For further information regarding the study, contact study doctor: Dr K.Govender 
0836500980. 
Alternatively you may contact the following study volunteer: 
 Dr T Hoffman- 0824151969 
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Appendix VI: Information Leaflet- Parent/Guardian 
 
PARTICIPANT INFORMATION LEAFLET FOR PARENT/GUARDIAN 
STUDY NUMBER:       DATE: 
PATIENT NUMBER:  
 
TITLE OF THE STUDY: AN ASSESSMENT OF THE IMPACT OF SEVERITY OF 
ATOPIC DERMATITIS ON THE QUALITY OF LIFE OF AFFECTED PATIENTS 
AND THEIR FAMILES. 
STUDY INVESTIGATOR: Dr K Govender 
INSTITUTION: University of the Witwatersrand 
 
To participant: This document may contain words that you do not understand. 
Please ask the study doctor to explain any words or information that you do not 
clearly understand. You may take home an unsigned copy of this information 
leaflet and consent form to think about or discuss with your family before making 
your decision as to whether to participate in this study or not. Before you agree to 
participate, it is important that you understand the purpose of the study and the 
procedures involved. This information leaflet is to help you to decide if you want to 
participate in this study. If you have any questions, do not hesitate to ask me. If 
you agree to participate, you will be asked to sign a consent form to confirm you 
understand the study procedure and that you are willing to participate. 
 
We are inviting you and your child to participate in a research study conducted at 
the paediatric dermatology outpatient clinic at Chris Hani Baragwanath Hospital. 
 
Your child has been diagnosed with atopic dermatitis. Atopic dermatitis is a 
chronic itchy skin problem that can affect any age group but usually occurs in 
children. It is not contagious. There may be a family history of eczema, asthma or 
runny nose.  
 
In this study, we want to learn how atopic dermatitis affects the daily activities and 
quality of life in your child, your family and yourself. These details cannot be 
assessed by us when we examine your child. That is why we want you to fill in a 
questionnaire yourself. By completing this questionnaire, you are helping us to 
learn if assessing quality of life in your family as a result of your child`s skin 
problem, is important in the treatment of your child. 
 
Participation in this study is being offered to all children less than 6 years old with 
atopic dermatitis and their parent/guardian. At your appointment, your child will be 
examined and the findings will be recorded in your child/ward’s file and on 
anonymous record sheets for the study. After that you will be asked to complete a 
questionnaire which is confidential. The study will be conducted over 3 months. 
You will only be required to fill in a questionnaire on one visit, therefore the total 
time required for your participation and that of your child in this study will be a 
maximum of 1 hour. 
 
Participation in this study is voluntary. You will not be discriminated against if you 
decide not to participate in this study. Your child will still receive all his/her 
medication. Your child will not be harmed in any way during the study. There are 
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no risks in this study. No medication will be tested on your child/ward. Your child 
will still continue with his/her normal treatment. If your child`s treatment is 
changed, it is because the state of his/her skin condition has changed and is not 
related to the study. There are no direct benefits to you or your child for 
participating in this study. You will not be paid for taking part in the study. 
 
All information obtained during the course of this study, including hospital records, 
personal data and research data will be strictly confidential. Data that may be 
reported in scientific journals will not include any information that identifies you as 
clinical participant in this study. The information might also be inspected by the 
University of the Witwatersrand, Human Research Committee. 
 
This study protocol has been submitted to the University of the Witwatersrand, 
Human Ethics Committee. If you require any information regarding your rights as a 
research participant, or have any complaints regarding this research, you may 
contact Prof Cleaton Jones, Chairperson of the University of the Witwatersrand, 
Human Research Ethics Committee established to help protect the rights of 
research participants at 011-717 2229. 
 
For further information regarding the study, contact study doctor: Dr K.Govender 
0836500980. 
Alternatively you may contact the following study volunteer: 
 Dr T Hoffman- 0824151969 
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Appendix VII 
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Appendix VIII 
 
   Patient- oriented eczema measure 
 
Patient Number: 
Study Number: 
 
For how many days in the last week has your child had the following symptoms: 
 
    0 days  1-2 days  3-4 days  5-6days  7 days  
1. dryness  
2. flakiness  
3. itching  
4. oozing  
5. bleeding  
6. cracking  
7. disturbed sleep  
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Appendix IX 
 
Childhood Atopic dermatitis Impact Scale 
Patient Number: 
Study Number: 
 
Please rate the following statements regarding the quality of life of your family over the 
last 4 weeks. Score each statement 0 to 4 depending on how strongly you agree with the 
statements. 0=never, 1=almost never, 2=sometimes, 3=often, 4=always 
 
1. The skin condition affects how well my child sleeps. 
2. Because of this skin condition, I limit my child’s outdoor activities such as playing 
in parks and beaches. 
3. My child’s skin condition affects how well my spouse and I sleep. 
4. I am bothered that this skin condition affects our vacation plans. 
5. The skin condition affects our social lives. 
6. This skin condition makes my child fussy and irritable. 
7. I am bothered that my family stays home more because of this skin condition. 
8. I am bothered that this skin condition affects our relationships with relatives. 
9. My child scratches or rubs his/her skin. 
10. This skin condition makes my child feel frustrated. 
11. I worry about leaving my child with others because of this skin condition. 
12. My child seems to cry more because of this skin condition. 
13. I worry that my child’s skin condition will continue. 
14. My child’s skin seems to be painful or irritated. 
15. I am frustrated with my child’s skin condition. 
16. I/We avoid taking photos of my child because of this skin condition. 
17. My child seems to be restless or hyperactive because of this skin condition. 
18. I am bothered by how much time is needed to care for my child’s skin condition. 
19. I worry about the costs of my child’s skin condition. 
20. My child’s skin condition affects my spouse’s or my work performance due to 
missed time and decreased productivity. 
21. Taking a bath makes my child uncomfortable. 
22. My child’s itching or scratching affects his/her play. 
23. I feel helpless about my child’s skin condition. 
24. My child scratches his/her skin to get attention. 
25. I am bothered by the reaction of strangers to this condition. 
26. I am disappointed that my child has this skin condition. 
27. Certain fabrics or clothes seem to bother my child’s skin. 
28. I worry that my child is exposed to things that may worsen this skin condition. 
29. It is difficult to discipline my child because of this skin condition. 
30. My child’s skin condition has strained my relationship with my spouse and partner. 
31. My child sleeps in my bed because of this skin condition. 
32. I worry about the side effects from treatments for this skin condition. 
33. I worry that this skin condition will affect my child’s ability to make friends. 
34. My child misbehaves more because of this skin condition. 
35. This skin condition has affected how confident I feel about my child’s medical care. 
36. I am bothered by my child sleeping in my bed. 
37. I am angry that my child has this skin condition. 
38. I worry that this skin condition will affect my child’s self-esteem. 
39. My child’s skin condition makes me feel sad or depressed. 
40. My child’s skin condition has affected my decision to have other children. 
41. Children seem to avoid touching or playing with my child because of this skin 
condition. 
42. I blame myself or feel guilty that my child has this skin condition. 
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43. My child dislikes having creams or ointments applied to his or her skin. 
44. I am embarrassed by the way my child’s skin looks. 
45. My child’s skin condition makes it hard to do what I enjoy. 
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Appendix X 
 
  Demographic details form 
 
Age of child: 
Sex of child: 
Race of child: 
Nature of caregiver: 
Age of caregiver: 
Race of caregiver: 
Religion of caregiver: 
Highest education achieved by caregiver: 
Occupation of caregiver: 
Marital status of caregiver: 
Does caregiver cohabitate with his/her partner: 
Household income: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
